» Articles » PMID: 38253698

Hypothyroidism and Hyperthyroidism Related to Gynecologic Cancers: a Nationwide Population-based Cohort Study

Overview
Journal Sci Rep
Specialty Science
Date 2024 Jan 22
PMID 38253698
Authors
Affiliations
Soon will be listed here.
Abstract

The purpose of this study was to assess the risks of hyperthyroidism and hypothyroidism related to gynecological cancers. Population-based retrospective cohort study. We conducted a cohort study using the Taiwan National Health Insurance Research Database to explore hyperthyroidism and hypothyroidism associated with site-specific gynecologic cancers in women from January 1, 2000 to December 31, 2018. The examined gynecologic cancers included endometrial (EC), uterine corpus cancer (UC), and ovarian cancer (OC). The incidence and hazard ratios were quantified using Cox proportional hazards models. The incidence of developing gynecological (Gyn) cancers in the hyperthyroid and hypothyroid women was 0.29 and 0.44 per 1000 person-years, which was 0.86 fold lower and 1.13 fold higher than that in the comparison cohort (p < 0.001). Compared with patients aged 20-40 years, patients in older age groups had a lower and higher risk of developing Gyn cancers (for hyperthyroid, 40-65 years: adjusted hazard ratio (aHR) = 0.82; > 65 years: aHR = 0.94; for hypothyroid, adjusted hazard ratio (aHR) = 1.26; > 65 years: aHR = 1.38). Compared with the non-hypothyroid women and non-hyperthyroid women beyond 6 years of follow-up, hypothyroid and hyperthyroid women showed decreased risk of Gyn cancers. Medication treatment for hyperthyroid and hypothyroid disease did not showed significant association in subgroup analyses (aHR = 0.99 and 0.80, respectively). Our results show that women with hyperthyroidism have a significantly reduced risk of gynecological cancers, whereas women with hypothyroidism have a slightly increased risk of gynecological cancers suggesting an association between thyroid function level and risk of gynecological cancers.

Citing Articles

Navigating the thyroid-gynecologic interplay: a systematic review and meta-analysis.

Ramadan H Obstet Gynecol Sci. 2024; 67(6):525-533.

PMID: 39317987 PMC: 11581810. DOI: 10.5468/ogs.24185.

References
1.
Horkko T, Tuppurainen K, George S, Jernvall P, Karttunen T, Makinen M . Thyroid hormone receptor beta1 in normal colon and colorectal cancer-association with differentiation, polypoid growth type and K-ras mutations. Int J Cancer. 2005; 118(7):1653-9. DOI: 10.1002/ijc.21556. View

2.
Minlikeeva A, Freudenheim J, Cannioto R, Eng K, Szender J, Mayor P . History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017; 117(7):1063-1069. PMC: 5625672. DOI: 10.1038/bjc.2017.267. View

3.
Ness R, Grisso J, Cottreau C, Klapper J, Vergona R, WHEELER J . Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. Epidemiology. 2000; 11(2):111-7. DOI: 10.1097/00001648-200003000-00006. View

4.
Klieverik L, Coomans C, Endert E, Sauerwein H, Havekes L, Voshol P . Thyroid hormone effects on whole-body energy homeostasis and tissue-specific fatty acid uptake in vivo. Endocrinology. 2009; 150(12):5639-48. DOI: 10.1210/en.2009-0297. View

5.
Yurkovetsky Z, Taasan S, Skates S, Rand A, Lomakin A, Linkov F . Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin. Gynecol Oncol. 2007; 107(1):58-65. PMC: 2777971. DOI: 10.1016/j.ygyno.2007.05.041. View